ChristopherRyanHeeryMD

PubMed

• 1 citations
  The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor.
  Liny John, Hannah Smith, Maran Ilanchezhian, Robin Lockridge, Karlyne M Reilly, Margarita Raygada, Eva Dombi, Abby Sandler, Barbara J Thomas, John Glod, Markku Miettin...> ;Pediatric Blood & Cancer. 2023 Jun 22
• Avelumab in Patients With Metastatic Colorectal Cancer.
  Jason M Redman, Geraldine O'Sullivan Coyne, Clay T Reed, Ravi A Madan, Julius Strauss, Seth J Steinberg, Jennifer Marté, Lisa Cordes, Christopher Heery, James L Gulley> ;The Oncologist. 2023 Sep 7
• 11 citations
  Dose fractionation of CAR-T cells. A systematic review of clinical outcomes.
  Matthew Frigault, Anand Rotte, Ayub Ansari, Bradford Gliner, Christopher Heery, Bijal Shah> ;Journal of Experimental & Clinical Cancer Research. 2023 Jan 10
• 13 citations
  Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
  Peter Joseph DeMaria, Katherine Lee-Wisdom, Renee N. Donahue, Ravi A. Madan, Fatima Karzai, Angie Schwab, Claudia Palena, Caroline Jochems, Charalampos S. Floudas, Jul...> ;Journal for Immunotherapy of Cancer. 2021 Sep 1
• 24 citations
  Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced,...
  Peter Joseph DeMaria, Marijo Bilusic, Deric M. Park, Christopher R. Heery, Renee N. Donahue, Ravi A. Madan, Mohammad Hadi Bagheri, Julius Strauss, Victoria Shen, Jenni...> ;The Oncologist. 2021 May 1
• 15 citations
  Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in A...
  Julie Collins, Renee N. Donahue, Yo-Ting Tsai, Michell Manu, Claudia Palena, Margaret E. Gatti-Mays, Jennifer L. Marte, Ravi A. Madan, Fatima Karzai, Christopher R. He...> ;The Oncologist. 2020 Jul 1
• 41 citations
  Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
  Houssein Abdul Sater, Jennifer L. Marte, Renee N. Donahue, Beatriz Walter-Rodriguez, Christopher R. Heery, Seth M. Steinberg, Lisa M. Cordes, Guinevere Chun, Fatima Ka...> ;Journal for Immunotherapy of Cancer. 2020 Mar 1
• 82 citations
  Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
  Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O'Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar...> ;Journal for Immunotherapy of Cancer. 2019 Oct 21
• 121 citations
  Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
  Phillip R. Pittman, Matthew Hahn, HeeChoon S. Lee, Craig D. Koca, Nathaly Samy, Darja Schmidt, Joachim Hornung, Heinz Weidenthaler, Christopher R. Heery, Thomas Meyer,...> ;The New England Journal of Medicine. 2019 Nov 13
• 147 citations
  Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
  Marijo Bilusic, Christopher R. Heery, Julie Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marte, Julius Strauss, Margaret E. Gat...> ;Journal for Immunotherapy of Cancer. 2019 Sep 5
• 38 citations
  A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
  Margaret E. Gatti-Mays, Julius Strauss, Renee N. Donahue, Claudia Palena, Jaydira Del Rivero, Jason M. Redman, Ravi A. Madan, Jennifer L. Marte, Lisa M. Cordes, Elizab...> ;Clinical Cancer Research. 2019 Aug 15
• 134 citations
  Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
  James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, N...> ;Journal of Clinical Oncology. 2019 Feb 28
• 89 citations
  First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors
  Julius Strauss, Christopher R. Heery, Joseph Kim, Caroline Jochems, Renee N. Donahue, Agnes S. Montgomery, Sheri McMahon, Elizabeth Lamping, Jennifer L. Marte, Ravi A....> ;Clinical Cancer Research. 2019 Jan 1
• 263 citations
  Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
  Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Ravi A. Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L. Marte, Renee N. Donahue, Italia Grenga, Li...> ;Clinical Cancer Research. 2018 Mar 15
• 45 citations
  Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
  Christopher R. Heery, Claudia Palena, Sheri McMahon, Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Ulrike Dirmeier, Lisa M. Cordes, Jennifer L. Marte, William L. ...> ;Clinical Cancer Research. 2017 Nov 15
• 47 citations
  A Blueprint to Advance Colorectal Cancer Immunotherapies.
  Dung T. Le, Vanessa M Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer, Thomas H. Marsilje, Arthur Nathan Brodsky, Emily Chan, Dustin A. Deming, Lui...> ;Cancer Immunology Research. 2017 Nov 1
• 134 citations
  Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group
  Silvia Stacchiotti, Alessandro Gronchi, Piero Fossati, Toru Akiyama, Claire Alapetite, Michael Baumann, J.-Y. Blay, Stéphanie Bolle, Stefano Boriani, P. Bruzzi, R. Cap...> ;Annals of Oncology. 2017 Jun 1
• 228 citations
  Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
  Christopher R. Heery, Geraldine O'Sullivan-Coyne, Ravi A. Madan, Lisa M. Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L. Marte, L...> ;The Lancet. Oncology. 2017 May 1
• 69 citations
  Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
  Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley, Jeffrey Schlom> ;Journal for Immunotherapy of Cancer. 2017 Feb 21
• 25 citations
  Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
  Benedetto Farsaci, Renee N. Donahue, Italia Grenga, Lauren M. Lepone, Peter S. Kim, Brendan E. Dempsey, Janet C. Siebert, Nuhad K. Ibrahim, Ravi A. Madan, Christopher ...> ;Cancer Immunology Research. 2016 Sep 2
• 9 citations
  Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST
  Kathleen E. Fenerty, Les R. Folio, Nicholas J. Patronas, Jennifer L. Marte, James L. Gulley, Christopher R. Heery> ;BMC Cancer. 2016 Aug 23
• 28 citations
  Samarium-153-EDTMP (Quadramet ® ) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
  Christopher R. Heery, Ravi A. Madan, Mark N. Stein, Walter M. Stadler, Robert S. DiPaola, Myrna Rauckhorst, Seth M. Steinberg, Jennifer L. Marte, Clara C. Chen, Italia...> ;Oncotarget. 2016 Jul 28
• 9 citations
  Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden?
  Kathleen E. Fenerty, Nicholas J. Patronas, Christopher R. Heery, James L. Gulley, Les R. Folio> ;Journal of Digital Imaging. 2016 Jun 1
• 86 citations
  The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
  Caroline Jochems, Massimo Fantini, Romaine I. Fernando, Anna R. Kwilas, Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Young-Seung Kim, Martin W. Brechbiel, James ...> ;Oncotarget. 2016 May 12
• 81 citations
  Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
  Rika Fujii, Eitan Friedman, Jacob Richards, Kwong Y. Tsang, Christopher R. Heery, Jeffrey Schlom, James W. Hodge> ;Oncotarget. 2016 May 9
• Join now to see all

Journal Articles

• Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma  
  Bilusic, M, Heery, CR, Arlen, PM, Rauckhorst, M, Apelian, D, Tucker, JA, Jochems, C, Schlom, J, Gulley, JL, Madan, RA, Cancer Immunol Immunother, 1/1/2014
• A phase I study of intraprostatic administration of PSA-TRICOM vaccine in men with locally recurrent or progressive prostate cancer  
  Gulley, JL, Heery, CR, Madan, RA, Walter, BA, Merino, MJ, Vergati, M, Poole, DJ, Cereda, V, Tsang, K, Dahut, WL, Schlom, J, Pinto, PA, Cancer Immunol Immunother, 1/1/2013
• Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer  
  Gulley, JL, Madan, RA, Heery, CR, Am Soc Clin Oncol Educ Book, 1/1/2013
• Clinical evaluation of TRICOM vector therapeutic cancer vaccines  
  Madan, RA, Bilusic, M, Heery, C, Schlom, J, Gulley, JL, Seminars in Oncology, 6/1/2012
• Unusual CNS presentation of thyroid cancer  
  Heery CR, Engelhard HH, Slavin KV, Michals EA, Villano JL, Clinical Neurology and Neurosurgery, 1/1/2012
• Combination of vaccine and immune checkpoint inhibitor safe with encouraging clinical activity  
  Madan, RA, Heery, CR, Gulley, JL, OncoImmunology, 1/1/2012
• Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response  
  Kim, JW, Bilusic, M, Heery, CR, Madan, RA, Cancers, 1/1/2012
• Combining radiation and therapeutic cancer vaccines: a synergistic approach  
  Heery, CR, Hodge, JW, Gulley, JL, Breast Cancer Manage, 1/1/2012
• Modern Immunotherapy for the treatment of prostate cancer  
  Heery, CR, Madan, RA, Drug Discov Today: Therapeutic Strategies, 1/1/2011
• Join now to see all

Books/Book Chapters

• Am Soc Clin Oncol Educ Book 
  Chapter: Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer. 
  Page 166 - 170GulleyJL, Madan RA, Heery CR2013
• DNA Topoisomerases and Cancer 
  Chapter: Topoisomerase II Inhibitors: Current Use and Prospects. 
  Olivier Mir, William Dahut, Francois Goldwasser, and Christopher Heery2012
• Emerging Cancer Therapeutics: Prostate Cancer 
  Chapter: Emerging treatment strategies for metastatic prostate cancer: The next step forward. 
  Heery CR, Bilusic M, Madan R2011
• ASCO Education Book 
  Chapter: Immune Targeting of Prostate Cancer. 
  Schlom J, Madan RA, Bilusic M, Heery CR, Hodge JW, Gulley JL2011
• Join now to see all

Abstracts/Posters

• Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
  Christopher Heery, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Androgen Deprivation Therapy on the Thymus and the Production of Naive T-cells.
  Madan RA, Hakim F, Jochems C, Heery CR, O'Sullivan GC, Singh H, Surolia I, Tsang KY, Gress R, Schlom J, Gulley J, SITC Annual Meeting, 1/1/2013
• Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination...
  Grenga I, Donahue RN, Kim PS, Dempsy B, Gulley JL, Heery CR, Madan RA, Schlom J, Farsaci B, J Clin Oncol, ASCO Breast Cancer Symposium, 1/1/2013
• A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer.
  Madan RA, Singh NK, Gramza AW, Fojo A, Heery CR, Kim JW, McMahon S, Rauckhorst M, King TH, Apelian D, Schlom J, Gulley JL, J Clin Oncol, ASCO Annual Meeting, 1/1/2013
• A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA TRICOM, in metastatic, castration resistant prostate cancer.
  Singh NK, Kim JW, Heery CR, Dahut WL, Couvillon A, Rauckhorst M, McMahon S, Schlom J, Fojo A, Arlen PM, Gulley JL, Madan RA, J Clin Oncol, ASCO Annual Meeting, 1/1/2013
• Safety profile of recombinant poxviral TRICOM vaccines.
  Kim JW, Marte JL, Singh NK, Heery CR, Madan RA, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Kantoff PW, Gulley JL, J Clin Oncol, ASCO Annual Meeting, 1/1/2013
• A phase 2 randomized clinical trial of Samarium-153 EDTMP (Sm-153) +/- PSA-TRICOM vaccine in metastatic castration resistant prostate cancer (mCRPC) after docetaxel.
  C. Heery, R. Madan, M. Bilusic, J. Kim, N. Singh, M. Rauckhorst, S. Steinberg, W. Dahut, C. Chen, R. DiPaola, M. Stein, W. Stadler, D. Panicali, J. Hodge, J. Schlom, J..., GU ASCO Meeting, 1/1/2013
• Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa.
  Gulley JL, Madan RA, Stein WD, Wilkerson J, Dahut WL, Heery CR, Schlom J, Wilding G, DiPaola RS, J Clin Oncol, ASCO Genitournary Cancers Symposium, 1/1/2013
• Safety profile of poxviral vaccines: NCI experience.
  Kim JW, Marte JL, Bilusic M, Singh NK, Heery CR, Madan RA, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Gulley JL, J Clin Oncol, Genitourinary Cancers Symposium, 1/1/2013
• A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC1-TRICOM.
  C. Heery, N. Ibrahim, R. Madan, M. Mohebtash, P. Arlen, M. Bilusic, J. Kim, N. Singh, S. McMahon, S. Hodge, S. Steinberg, J. Schlom, J. Hodge, J. Gulley, San Antonio Breast Cancer Symposium, 1/1/2012
• A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC1-TRICOM.
  C. Heery, N. Ibrahim, R. Madan, M. Mohebtash, P. Arlen, M. Bilusic, J. Kim, N. Singh, S. McMahon, S. Hodge, S. Steinberg, J. Schlom, J. Hodge, J. Gulley, ESMO Annual Meeting, 1/1/2012
• Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer ...
  C.R. Heery, R.A. Madan, M. Bilusic, J.W. Kim, N.K. Singh, M. Rauckhorst, C. Chen, W.L. Dahut, W.M. Stadler, R.S. DiPaola, M.N. Stein, J.W. Hodge, J. Schlom, J.L.Gulley, J Clin Oncol, ASCO Annual Meeting, 1/1/2012
• First-in-human phase I trial of NHS-IL12 in advanced solid tumors.
  Kim JW, Heery CR, Bilusic M, Singh NK, Madan RA, Sabzevari H, Schlom J, Gulley JL, J Clin Oncol, ASCO Annual Meeting, 1/1/2012
• A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFI...
  Marshall J, Hwang JJ, Pishvaian MJ, He AR, Weiner LM, Sandene EK, Gulley JL, Heery CR, Schlom J, Speyer S, Richman J, Ferraro J, Coeshott C, Cohn A, Appelian D, Rodell TC, J Clin Oncol, ASCO Annual Meeting, 1/1/2012
• A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA expressing cancers.
  M. Bilusic, J.L. Gulley, J.W. Hodge, K.Y. Tsang, P. M. Arlen, C.R. Heery, M. Rauckhorst, S. McMahon, C. Intrivici, D. Poole, C. Jochems, J. Schlom, R.A. Madan, J Clin Oncol, 1/1/2012
• Combining Vaccines with other therapeutics: A strategy to accelerate proof of concept studies?
  Gulley J.L., Heery C.R., Bilusic M., Kim J., Stadler W., DiPaola R., Ibrahim N., Madan R., Society for Immunotherapy of Cancer Annual Meeting, 11/1/2011
• Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer.
  C.R. Heery, P. A. Pinto, J. Schlom, K.Y. Tsang, R.A. Madan, D. Poole, M. Vergati, B. Walter Rodriguez, M. Merino, J.L. Gulley, J Clin Oncol, ASCO Annual Meeting, 1/1/2011
• A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA.
  R.A. Madan, M. Bilusic, J. W. Hodge, K.Y. Tsang, P. M. Arlen, C.R. Heery, M. Rauckhorst, S. McMahon, C. Intrivici, T. A. Ferrara, A. Cohn, D. Apelian, A. Franzusoff, Z..., J Clin Oncol, 1/1/2011
• Intraprostatic vaccine administration in patients with locally recurrent prostate cancer.
  Heery CR, Pinto PA, Schlom J, Tsang KY, Madan RA, Poole D, Vergati M, Walter Rodriguez B, Merino M, Gulley JL, J Clin Oncol, 1/1/2011
• Immune Targeting of Prostate Cancer.
  Schlom J, Madan RA, Bilusic M, Heery CR, Hodge JW, Gulley JL, GU ASCO Presentation, 1/1/2011
• A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC).
  M. Bilusic, J. L. Gulley, C. Heery, A. B. Apolo, P. M. Arlen, M. Rauckhorst, S. McMahon, W. L. Dahut, J. Schlom, R. A. Madan, J Clin Oncol, 1/1/2011
• Prostvac: A promising new therapeutic vaccine for Prostate Cancer.
  Gulley JL, Madan RA, Heery CR, Bilusic M, Dahut W, Schlom, J, Society of Urologic Oncology, 12/1/2010
• Flutamide with or without a Poxviral-based Therapeutic Cancer Vaccine in patients with nonmetastatic Castration-Resistant Prostate Cancer (CRPC).
  Madan RA, Bilusic M, Heery CR, Apolo AB, Arlen PM, Dahut WL, Schlom J, Gulley JL, Society of Urologic Oncology, 12/1/2010
• Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade g...
  Heery CR, Desjardins A, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Friedman AH, Reardon DA, and Friedman HS, Journal of Clinical Onocology, ASCO Annual Meeting Proceedings, 1/1/2006
• Join now to see all